-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
Sensitivity analysis of the group who had an exacerbation before the index date.
Published 2022Subjects: -
170
-
171
-
172
-
173
-
174
Image_1_Decreased Endometrial Thickness Is Associated With Higher Risk of Neonatal Complications in Women With Polycystic Ovary Syndrome.tif
Published 2021“…</p>Conclusion<p>Decreased EMT was independently associated with increased risk of PTB, LBW and SGA in women with PCOS.…”
-
175
Image_2_Decreased Endometrial Thickness Is Associated With Higher Risk of Neonatal Complications in Women With Polycystic Ovary Syndrome.tif
Published 2021“…</p>Conclusion<p>Decreased EMT was independently associated with increased risk of PTB, LBW and SGA in women with PCOS.…”
-
176
Table_1_Decreased Endometrial Thickness Is Associated With Higher Risk of Neonatal Complications in Women With Polycystic Ovary Syndrome.docx
Published 2021“…</p>Conclusion<p>Decreased EMT was independently associated with increased risk of PTB, LBW and SGA in women with PCOS.…”
-
177
-
178
APOL1 risk variant expression in HeLa cells leads to lipid accumulation in the absence of decreased cholesterol efflux.
Published 2019“…There were no statistically significant differences in cholesterol efflux that were detected in this system.…”
-
179
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
180
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”